Rewriting the textbook for pharma: how to adapt and thrive in a digital, personalized and collaborative world

IF 6.5 2区 医学 Q1 PHARMACOLOGY & PHARMACY Drug Discovery Today Pub Date : 2024-07-23 DOI:10.1016/j.drudis.2024.104112
Charles H. Jones, Subha Madhavan, Kannan Natarajan, Michael Corbo, Jane M. True, Mikael Dolsten
{"title":"Rewriting the textbook for pharma: how to adapt and thrive in a digital, personalized and collaborative world","authors":"Charles H. Jones,&nbsp;Subha Madhavan,&nbsp;Kannan Natarajan,&nbsp;Michael Corbo,&nbsp;Jane M. True,&nbsp;Mikael Dolsten","doi":"10.1016/j.drudis.2024.104112","DOIUrl":null,"url":null,"abstract":"<div><p>The pharmaceutical industry is undergoing a sweeping transformation, driven by technological innovations, demographic shifts, regulatory changes and consumer expectations. For adaptive players in pharma to excel in this rapidly changing landscape, which will be markedly different from today by 2030 and beyond, they will require a different set of skills, capabilities and mindsets, as well as a willingness to collaborate and co-create value with multiple stakeholders. The industry needs to rewrite the textbook for pharma by embracing and implementing four key dimensions of change: digitalization, personalization, collaboration and innovation. In this article, we will examine how these dimensions of change are reshaping the industry, and provide practical and strategic guidance based on best practices and examples. Specifically, adaptive pharma companies should embrace the use of advanced digital technologies, such as artificial intelligence and machine learning, to streamline processes and solve challenges rapidly. Personalization, both in medicine and patient engagement, will also be key to success in the ‘digital revolution’, and a collaborative approach involving partnerships with tech start-ups, health-care providers and regulatory bodies will also be essential to create an integrated and responsive health-care ecosystem. Using these ideas for a rewritten textbook for pharma, adaptive players in pharma will evolve to be personalized and digitized health-focused organizations that provide comprehensive solutions which go beyond drugs and devices.</p></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 9","pages":"Article 104112"},"PeriodicalIF":6.5000,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S135964462400237X/pdfft?md5=0c9094726fd2d934efaf51c6879e51b3&pid=1-s2.0-S135964462400237X-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S135964462400237X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

The pharmaceutical industry is undergoing a sweeping transformation, driven by technological innovations, demographic shifts, regulatory changes and consumer expectations. For adaptive players in pharma to excel in this rapidly changing landscape, which will be markedly different from today by 2030 and beyond, they will require a different set of skills, capabilities and mindsets, as well as a willingness to collaborate and co-create value with multiple stakeholders. The industry needs to rewrite the textbook for pharma by embracing and implementing four key dimensions of change: digitalization, personalization, collaboration and innovation. In this article, we will examine how these dimensions of change are reshaping the industry, and provide practical and strategic guidance based on best practices and examples. Specifically, adaptive pharma companies should embrace the use of advanced digital technologies, such as artificial intelligence and machine learning, to streamline processes and solve challenges rapidly. Personalization, both in medicine and patient engagement, will also be key to success in the ‘digital revolution’, and a collaborative approach involving partnerships with tech start-ups, health-care providers and regulatory bodies will also be essential to create an integrated and responsive health-care ecosystem. Using these ideas for a rewritten textbook for pharma, adaptive players in pharma will evolve to be personalized and digitized health-focused organizations that provide comprehensive solutions which go beyond drugs and devices.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
改写制药业的教科书:如何在数字化、个性化和协作化的世界中适应和发展。
在技术创新、人口结构变化、监管变化和消费者期望的推动下,制药行业正在经历一场翻天覆地的变革。到 2030 年及以后,医药行业的格局将与今天大不相同,要想在这一瞬息万变的格局中脱颖而出,适应性强的制药企业需要具备不同的技能、能力和思维方式,并愿意与多个利益相关方合作,共同创造价值。制药业需要通过接受和实施四个关键维度的变革来重写制药业的教科书:数字化、个性化、协作和创新。在本文中,我们将探讨这些变革维度是如何重塑行业的,并根据最佳实践和实例提供实用的战略指导。具体来说,适应性制药公司应拥抱先进数字技术的使用,如人工智能和机器学习技术,以简化流程并快速解决挑战。医药和患者参与方面的个性化也将是 "数字革命 "成功的关键,而与初创科技公司、医疗服务提供商和监管机构合作的方法对于创建一个整合的、反应迅速的医疗生态系统也至关重要。利用这些理念改写制药业的教科书,适应性制药企业将发展成为以个性化和数字化健康为重点的组织,提供超越药物和设备的全面解决方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Drug Discovery Today
Drug Discovery Today 医学-药学
CiteScore
14.80
自引率
2.70%
发文量
293
审稿时长
6 months
期刊介绍: Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed. Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports.
期刊最新文献
Nondestructive techniques in pharmaceutical drug product characterization. Redefining what it means to age - the impact to society and pharmaceutical industry. Mapping epilepsy biomarkers: a bibliometric and content analysis. Efficacy and challenges involving combination therapies in CLL. Strategic partnerships for AI-driven drug discovery: The role of relational dynamics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1